Johnson & Johnson will receive 100 million euros, approximately $115 million, to support the development of their Ebola vaccine, the company announced Friday.

The money comes from the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative that aims to speed up the development of safer and better medicines. IMI will be distributing the funds through grants to Johnson & Johnson’s newly formed consortium that includes the London School of Hygiene & Tropical Medicine, the University of Oxford, and La Centre Murazhe.

In October, the U.S. company committed up to $200 million to accelerate their Ebola vaccine. The company has since been seeking partners in the venture.

Earlier this month, the company announced that it was beginning the first human trials of their two-injection vaccine. Further study will determine the dosage of the first ‘primer’ injection and the optimal period to wait until the second injection.

“In the face of the global challenge of Ebola, bringing together the expertise and capabilities of the pharmaceutical industry, academic centers and NGOs will be critical to help solve this crisis,” said Paul Stoffels, M.D., Chief  Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “The European Commission’s support through the IMI bolsters collaboration that should significantly accelerate efforts to help address this humanitarian crisis.”

Funding for IMI’s Ebola program comes in part from Horizon 2020, the European Union’s research and innovation program, and in part from contributions from the European Federation of Pharmaceutical Industries and Associations partners in the projects.

“It is great to see the multiple partners come together to accelerate the development of an effective vaccine both for the current epidemic and future outbreaks,” said Professor Peter Piot, M.D., director of the London School of Hygiene and Tropical Medicine. “This is an opportunity to make sure that this is the last Ebola epidemic in which our only tools to control it are isolation and quarantine.”

The 2014 Ebola outbreak is the worst outbreak in history, with over 8,000 deaths reported. More than 20,000 people have been infected in West Africa since the beginning of the outbreak. The size of the outbreak has given pharmaceutical companies incentive to speed up the development of possible vaccines.

Two rival companies are also well into developing their own Ebola vaccines. GlaxoSmithKline has announced plans to start human trials in February. Merck and NewLink has resumed their clinical trials at a lowered dosage.